Indications |
Nasal Seasonal allergic rhinitis Adult: As metered-dose nasal spray (0.06%): 42 mcg into each nostril bid/tid, up to 84 mcg into each nostril 3-4 times daily for up to 4 days when rhinorrhoea is associated with common cold or up to 3 wk in seasonal allergic cases. Child: As metered-dose nasal spray: ≥6 yr: 42 mcg into each nostril bid/tid. Nasal Rhinorrhoea associated with rhinitis Adult: As metered-dose nasal spray (0.06%): 42 mcg into each nostril bid/tid, up to 84 mcg into each nostril 3-4 times daily for up to 4 days when rhinorrhoea is associated with common cold or up to 3 wk in seasonal allergic cases. Child: As metered-dose nasal spray: ≥6 yr: 42 mcg into each nostril bid/tid. Inhalation Chronic obstructive pulmonary disease Adult: As metered-dose aerosol: 20 or 40 mcg 3 or 4 times daily. Max: 12 inhalations daily. As dry powder: 40 mcg 3 or 4 times daily. Max: 320 mcg daily. As nebulised solution: 500 mcg (1 unit dose vial) 3-4 times daily. Child: As metered-dose aerosol: <6 yr: 20 mcg tid; 6-12 yr: 20 or 40 mcg tid. As nebulised solution: <6 yr: 125-250 mcg; 6-12 yr: 250 mcg at intervals of at least 6 hr up to 1 mg daily. |
Warnings / Precautions |
Bladder neck obstruction, narrow-angle glaucoma or patients susceptible to glaucoma, prostatic hyperplasia. Protect patient's eyes from nebulised drug. Renal and hepatic impairment. Pregnancy, lactation, children, elderly. |
Adverse Reactions |
Dry mouth, urinary retention, buccal ulceration, paralytic ileus, headache, nausea, constipation, paradoxical bronchospasm, immediate hypersensitivity reactions (urticaria, angioedema), acute angle-closure glaucoma, nasal dryness and epistaxis (nasal spray). Potentially Fatal: Anaphylactic reactions, atrial fibrillation, supraventricular tachycardia. |
Drug Interactions |
Increased toxicity with other anticholinergic drugs. See Below for More ipratropium bromide Drug Interactions |
Mechanism of Actions |
Ipratropium bromide blocks the action of acetylcholine at parasympathetic sites in bronchial smooth muscle causing bronchodilation. Absorption: Poorly absorbed from the GIT. Distribution: Minimally protein-bound. Excretion: Via urine and faeces (as unchanged drug and metabolites). |
Storage Conditions |
Inhalation: Aerosol: Store at 25°C (77°F). Do not expose above 49°C (120°F). Solution: Store at 15-30°C (59-86°F). Nasal: Store tightly closed at 25°C (77°F). |
ATC Classification |
R01AX03 - ipratropium bromide ; Belongs to the class of other nasal preparations for topical use. R03BB01 - ipratropium bromide ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, anticholinergics. |
Storage |
Inhalation: Aerosol: Store at 25°C (77°F). Do not expose above 49°C (120°F). Solution: Store at 15-30°C (59-86°F). Nasal: Store tightly closed at 25°C (77°F). |
Available As |
|
Ipratropium
Post Review about Ipratropium Click here to cancel reply.
Ipratropium Containing Brands
Ipratropium is used in following diseases
Drug - Drug Interactions of Ipratropium
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.